05Jun 2022
Delaying Invasive Treatment in Unilateral Head and Neck Lymphatic Malformation Improves Outcomes

Delaying Invasive Treatment in Unilateral Head and Neck Lymphatic Malformation Improves Outcomes

This report evaluates head and neck lymphatic malformations (HNLMs) treatment outcomes. It presents a relative risk analysis of whether delaying invasive therapy reduces treatment number and risk. Delaying treatment in grade 1 HNLMs reduces invasive treatment number, but in grade 2 malformations this strategy does not reduce number of treatments. Observation and delayed IT in stage I–III HNLM (“Grade 1”) is safe and reduces IT (i.e., ≤1 IT). Stage IV–V HNLMs (“Grade 2”) with early IT have a greater risk of multiple ITs.

  • #ent

Like

Save

Share